| 摘要 |
The invention relates to methods for attenuating xenograft rejection in humans and old world monkeys, using oligosaccharides containing a Gal alpha 1-3Gal motif, to neutralize or remove anti- alpha Gal antibodies. The invention additionally relates to methods for site directed activation of the complement cascade or host leukocytes using oligosaccharides containing a Gal alpha 1-3Gal motif to target anti- alpha Gal antibodies. The invention further relates to pharmaceutical compositions that may be used in the practice of the invention. Such compositions contain, as the active ingredient, an oligosaccharide containing a Gal alpha 1-3Gal motif effective in binding anti- alpha Gal antibodies in vivo or ex vivo. |
